BioCryst Pharmaceuticals Inc
(MEX:BCRX)
MXN
170
0 (0%)
Market Cap: 31.93 Bil
Enterprise Value: 41.42 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 78/100 BioCryst Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020 / 01:00PM GMT
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP
Good morning, everybody. Thanks for joining us at the Bank of America Healthcare Conference. I am Tazeen Ahmad, one of the senior biotech analysts here at the firm. It is my pleasure this morning to have our next presenting company, BioCryst Pharmaceuticals. Speaking for BioCryst this morning will be Chief Executive Officer, Jon Stonehouse. Jon, good morning
Jon P. Stonehouse
BioCryst Pharmaceuticals, Inc. - CEO, President & Director
Good morning, Tazeen.
Tazeen Ahmad;Jon P. Stonehouse
BofA Merrill Lynch, Research Division - VP;BioCryst Pharmaceuticals, Inc. - CEO,
Thanks for joining us, and we're looking forward to spending the next 30 minutes with you. As an introduction, maybe you can give a 2-minute summary of BioCryst, the purpose of the company and some recent accomplishments for anybody on the line that may not be as familiar with your story. And then we can start talking about some exciting upcoming catalysts.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot